Search company, investor...

Predict your next investment

Corporation
curraxpharma.com

See what CB Insights has to offer

About Currax Pharmaceuticals

Currax Pharmaceuticals is a specialty pharmaceutical business focused on acquiring and commercializing prescription drugs within the US market. Currax distributes a range of both branded and generic pharmaceutical products.

Headquarters Location

10 North Park Place Suite 201

Morristown, New Jersey, 07960,

United States

800-793-2145

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Currax Pharmaceuticals News

Obesity Management Market is expected to reach US$ 1.3 Billion by 2031

Oct 5, 2022

Obesity Management Market is expected to reach US$ 1.3 Billion by 2031 Globally, more than 1 billion individuals are overweight or obese and the numbers continue rising. This high prevalence of obesity will drive demand for  obesity management  products and services in the long term. According to the World Health Organization (WHO), approximately 1.9 billion adults were overweight and 650 million adults were obese. Whereas 38.3 million children under 5 years of age were either overweight or obese in 2019. One in three adults in North America is obese. In the U.S., 80 million adults and 12.7 million children suffer from obesity. Obesity is a prominent community health problem in many parts of the world. It is associated with numerous health disorders including gallbladder disease, heart disease, diabetes, stroke, hypertension, and fatty liver disease in addition to some cancers. According to a recent Future Market Insights (FMI) report, the market is set to surpass US$ 1.2 Bn by the end of the forecast period in 2031, with a CAGR of over 5%. Furthermore, there has been an increase in the per capita healthcare expenditure, especially in developed countries, with better reimbursement policies. People are now inclined towards out-of-pocket expenditure healthcare. Personal health, grooming, and concerns over social discrimination are leading people to take obesity management consultations. However, the unprecedented pandemic crisis has had a significant impact on the obesity management market due to a slump of patient footfall in hospitals and clinics. Preference is now being given to the treatment of COVID-19 patients, limiting resources for anti-obesity consultations and related drugs or surgeries. Also, there has been a halt in clinical trials for weight management drugs. However, with the availability and commencement of the COVID-19 vaccination, the clinical trials are resuming and are anticipated to pick up pace during the forecast period. Also, the adoption of telehealth and in developing countries is likely to bode well for the future of the market in the long term. Ask from Market Research Expert –  https://www.futuremarketinsights.com/ask-question/rep-gb-587 Key Takeaways from Obesity Management Market Study Bupropion and Naltrexone will reflect register faster growth at a CAGR of 8.4%, owing to an increase in the preference for combination therapy in weight management. Gastric sleeve surgery will account for over 40% of the market throughout the forecast period owing to benefits of simplicity and time-efficiency. The U.S. will lead the North America market with a share of over 64% in 2021, driven by continuing diet and lifestyle issues prevalent in the country. Germany followed by Russia are leading markets in Europe, reflecting CAGR of over 6% through the end of 2031, driven by improvements in public health programs. Japan dominates the East Asia market, accounting for 49% value share in 2021, with government awareness programs contributing to growth. “The rapidly increasing obesity cases and the resultant chronic diseases have triggered concern among patients and healthcare professionals. The COVI-19 crisis has alarmed people, as overweight people are at higher risk of acquiring SARS-COV2. This consciousness may help in encouraging obesity management uptake through 2021 and beyond,” says the FMI analyst. Key Participant Insights Prominent players in the Obesity Management Market are focusing on collaborations, mergers & acquisitions for global expansion and enhanced opportunities focused on emerging economies thereby, enhancing their market presence. The key market players covered by FMI include GlaxoSmithKline Plc., VIVUS, Inc., Novo Nordisk A/S, Currax Pharmaceuticals LLC, Cheplapharm Arzneimittel GmbH, Bausch Health Companies Inc., and Takeda Pharmaceuticals, Inc. For in-depth insights, Download a PDF Brochure –  https://www.futuremarketinsights.com/reports/brochure/rep-gb-587 Obesity Management Market by Category By Drug Type:

Currax Pharmaceuticals Acquisitions

1 Acquisition

Currax Pharmaceuticals acquired 1 company. Their latest acquisition was Nalpropion Pharmaceuticals on September 27, 2019.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

9/27/2019

$99M

Acquired

2

Date

9/27/2019

Investment Stage

Companies

Valuation

$99M

Total Funding

Note

Acquired

Sources

2

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.